Join Our Free Newsletter
Get a weekly round-up of news on psychedelics, as well as the occasional article, by joining our free newsletter. For more, including our monthly patent analysis and tracker, join Pα+.
5-MeO-DMT Patent Tracker
Powered by
We’ve pulled together all of the 5-MeO-DMT-related patents and published patent applications that were filed in the U.S. or that later may be filed in the U.S. and become a U.S. patent (as discussed in further detail here).
“DMT” generally refers to the compound N,N-dimethyltryptamine, but because of the interest in both (and because many applications cover both) we’re collecting those related to 5-methoxy-N,N-dimethyltraptamine (5-MeO-DMT) as well as N,N-DMT. This table reflects applications pertaining to 5-MeO-DMT.
The compound 5-methoxy-N,N-dimethyltraptamine (5-MeO-DMT) was first synthesized by the Japanese chemist Toshio Hoshino in 1936, and isolated as one of the psychoactive ingredients of Anadenanthera peregrina seeds in 1959. However (as with DMT), plant extracts and other botanical preparations of 5-MeO-DMT have long been used among indigenous cultures. (More background here.)
Numerous patents on 5-MeO-DMT have been filed, with many granted, on pharmaceutical compositions, administration and treatment methods, and chemical and biosynthetic processes of production. The claimed uses of 5-MeO-DMT—from treating cognitive dysfunction, alleviating the effects of headache disorders, and to treating inflammatory disorders—vary broadly, and beyond just for psychiatric indications. For instance, Harvard College and the NIH filed an application on using 5-MeO-DMT as a “novel rodent control agent.”
It’s important to note that patent applications are kept secret for at least 18 months after filing. So if you came looking for one of the many applications recently announced by a company in the space, it won’t be reflected here. But keep checking back—we’ll update this table whenever new 5-MeO-DMT-related applications become public, and we’ll continue to add new tables for other psychedelic compounds (along with our existing psilocybin, MDMA, DMT, LSD, ketamine, and ibogaine tables), and post new articles discussing IP in the psychedelics space in the months to come.
This page is best viewed on a larger screen.
Click here to email it to yourself.
Note: The applications and patents in the table include all U.S. and PCT filings with substantive claims to 5-MeO-DMT compositions, formulations, and methods of use or production (including to certain analogs and derivatives). Applications or patents filed in other jurisdictions, or those where 5-MeO-DMT is only referenced incidentally, are not included. Where a PCT application has already entered prosecution in the U.S., typically the U.S. application is included. Only one of a family of multiple applications is generally listed, unless the others have separate significance. “Priority date” refers to the earliest filing date on which an applicant can rely (typically, the filing date of a U.S. provisional); it is used to determine who filed first and what public information is “prior art.”
